FY2025 EPS Estimates for Krystal Biotech Lowered by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at Chardan Capital cut their FY2025 earnings per share (EPS) estimates for Krystal Biotech in a note issued to investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now expects that the company will earn $5.50 per share for the year, down from their prior forecast of $6.15. Chardan Capital has a "Buy" rating and a $219.00 price objective on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share.

Several other equities analysts have also weighed in on KRYS. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Guggenheim cut their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $218.63.

Krystal Biotech Trading Down 3.6%

Shares of Krystal Biotech stock opened at $132.23 on Monday. The company's 50-day moving average price is $171.56 and its two-hundred day moving average price is $170.01. Krystal Biotech has a 52 week low of $131.71 and a 52 week high of $219.34. The stock has a market cap of $3.82 billion, a PE ratio of 44.22 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This trade represents a 5.62% decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of KRYS. Fifth Third Bancorp lifted its position in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Krystal Biotech in the 3rd quarter valued at approximately $40,000. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $95,000. Covestor Ltd boosted its stake in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after buying an additional 642 shares during the period. Finally, Avanza Fonder AB acquired a new stake in shares of Krystal Biotech during the 4th quarter valued at $119,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.